Please login to the form below

Not currently logged in
Email:
Password:

EC approves GSK's Tyverb for breast cancer

The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib) as a treatment for breast cancer

The European Commission (EC) has approved an additional use of GlaxoSmithKline's (GSK) Tyverb (lapatinib), in combination with an aromatase inhibitor, as a treatment for post-menopausal women with hormone receptor-positive, HER2 over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended.

The approval follows a positive recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2010.

According to a consensus forecast compiled by Thomson Reuters, sales of Tyverb in the US (where the drug is sold as Tykerb), are expected to reach around $375m in 2014.

Earlier this month, draft guidance issued by the UK's National Institute for Health and Clinical Excellence (NICE), recommended against the use of Tyverb outside of clinical trials. 

In the US, the Food and Drug Administration (FDA) approved the expanded use of Tyverb in combination with Novartis' Femara (letrozole)  - an aromatase inhibitor, in February 2010.

24th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics